0001104659-24-047511.txt : 20240416 0001104659-24-047511.hdr.sgml : 20240416 20240416080831 ACCESSION NUMBER: 0001104659-24-047511 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240416 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Cost Associated with Exit or Disposal Activities ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240416 DATE AS OF CHANGE: 20240416 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA, INC. CENTRAL INDEX KEY: 0001299130 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 161590339 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-34899 FILM NUMBER: 24846149 BUSINESS ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650-521-8000 MAIL ADDRESS: STREET 1: 1305 O'BRIEN DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 FORMER COMPANY: FORMER CONFORMED NAME: PACIFIC BIOSCIENCES OF CALIFORNIA INC DATE OF NAME CHANGE: 20050829 FORMER COMPANY: FORMER CONFORMED NAME: NANOFLUIDICS INC DATE OF NAME CHANGE: 20040729 8-K 1 tm2411926d1_8k.htm FORM 8-K
false 0001299130 0001299130 2024-04-16 2024-04-16 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported)

April 16, 2024

 

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

 

Delaware   001-34899   16-1590339
(State or other jurisdiction
of incorporation)
  (Commission
File Number)
  (IRS Employer
Identification No.)

 

1305 O’Brien Drive

Menlo Park, California 94025

(Address of principal executive offices) (Zip Code)

 

(650) 521-8000

(Registrant’s telephone number, including area code)

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading
Symbol(s)
  Name of each exchange
on which registered
Common Stock, par value $0.001 per share   PACB   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

ITEM 2.02.RESULTS OF OPERATIONS AND FINANCIAL CONDITION.

 

On April 16, 2024, Pacific Biosciences of California, Inc. (the “Company”) issued a press release providing a business update and announcing certain unaudited preliminary financial results as of and for the quarter ended March 31, 2024 (the “Press Release”). A copy of the Press Release is furnished hereto as Exhibit 99.1 and is incorporated by reference herein.

 

The information in Item 2.02 of this Current Report on Form 8-K, including the sections of the Press Release incorporated by reference herein, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

ITEM 2.05.COSTS ASSOCIATED WITH EXIT OR DISPOSAL ACTIVITIES.

 

On April 16, 2024, the Company announced a plan to reduce its annualized run-rate operating expenses on a non-GAAP basis by $50 million to $75 million by the end of 2024 in relation to the Company’s prior guidance of 5% operating expense growth. This plan is designed to better align the Company’s organizational structure and resources with its strategic initiatives. At this time, the Company is unable to make a determination of the estimated amount or range of amounts for charges to be incurred in connection with these actions. The Company will provide further details by amendment to this Current Report on Form 8-K at such time as it is able to estimate the costs the Company expects to incur.

 

This Item 2.05 contains forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements include, but are not limited to, statements related to the Company’s expected operating expense reductions, the expected timing of such reduction and the charges and financial impact associated with such reductions. These forward-looking statements are based on the Company’s current expectations and inherently involve significant risks and uncertainties. The Company’s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of those risks and uncertainties, which include, without limitation, risks related to the Company’s operating expense reductions and the Company’s ability to accurately estimate the charges associated with such reductions. Other factors that could cause actual results to differ from these forward-looking statements are discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. In addition, the charges associated with the Company’s operating expense reductions may be greater than anticipated. The Company’s operating expense reductions may have an adverse impact on the Company’s business and results of operations. Readers should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. The Company disclaims any obligation to update information contained in any forward-looking statements contained in this Item 2.05 whether as a result of new information, future events, or otherwise.

 

ITEM 8.01.OTHER EVENTS.

 

The information set forth in the Press Release, solely to the extent such information references the Company’s expectations for preliminary revenue estimates for the quarter ended March 31, 2024 and preliminary cash, cash equivalents and investments balance as of March 31, 2024, together with the paragraph set forth under the heading “Forward-looking statements”, is incorporated by reference into Item 8.01 of this Current Report on Form 8-K.

 

The portions of the Press Release incorporated by reference into Item 8.01 of this Current Report on Form 8-K are being filed pursuant to Item 8.01. The remaining portions of the Press Release are being furnished pursuant to Item 2.02 of this Current Report on Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Because the Company’s financial statements as of and for the quarter ended March 31, 2024 have not yet been finalized or audited and remain subject to change, the Company’s final results for such periods may differ materially from the unaudited preliminary financial information included in the Press Release. Accordingly, you should not place undue reliance on the unaudited preliminary financial information included in the Press Release.

 

ITEM 9.01.FINANCIAL STATEMENTS AND EXHIBITS.

 

(d) Exhibits.
   
99.1 Press Release issued by Pacific Biosciences of California, Inc. dated April 16, 2024
   
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Pacific Biosciences of California, Inc.
     
  By: /s/ Brett Atkins
    Brett Atkins
    General Counsel
Date: April 16, 2024    

  

 

 

EX-99.1 2 tm2411926d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

 

PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance

 

Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million

 

Q1 2024 Earnings Conference Call Scheduled for May 9, 2024

 

MENLO PARK, Calif. – April 16, 2024 /PRNewswire/ – PacBio (NASDAQ: PACB) today announced preliminary, unaudited revenue for the quarter ended March 31, 2024.

 

Preliminary First Quarter Results

 

·Preliminary revenue of $38.8 million, roughly flat compared with $38.9 million in the prior-year period.

·Instrument revenue of $19.0 million compared with $20.7 million in the prior-year period.

·Consumables revenue of $16.0 million compared with $14.0 million in the prior-year period. Expect Revio consumables in the first quarter of 2024 to be approximately $11.0 million.

·Service and other revenue of $3.8 million compared with $4.2 million in the prior-year period.

·Instrument revenue included 28 RevioTM sequencing systems in the first quarter of 2024, bringing the ending installed base to 201 systems as of March 31, 2024. Of the 28 Revio systems shipped, 16 were shipped to new customers. Onso shipments increased sequentially as PacBio continued to ramp up its manufacturing capacity, achieving steady-state production levels at the end of the quarter.

·Total preliminary cash, cash equivalents, and investments balance as of March 31, 2024 of approximately $562 million.

 

Preliminary revenue for the first quarter was below the company’s expectations due to an increasing number of customers delaying instrument purchases and softness in consumable shipments.

 

All regions underperformed, with 13 Revio systems falling out of the forecast in the last couple of weeks in the first quarter, which the company believes primarily resulted from elongated customer purchasing cycles. The median sales cycle for Revio instrument purchases increased more than expected in the first quarter of 2024. PacBio believes that these instruments continue to be strong sales opportunities that are likely to close in 2024. PacBio believes additional reasons for the shortfall include:

 

·The uncertainty surrounding the funding for new capital equipment, particularly in the U.S. and China;

·Procurement delays;

·Small-to-mid-size existing customers yet to increase their sample volumes to drive an upgrade to Revio; and,

·An increasing proportion of the sales pipeline was comprised of new customers in the first quarter of 2024, which have shown they have longer sales cycles compared to existing PacBio customers.

 

Consumable revenue was also below expectations, which the company believes was primarily attributed to: `

 

  · Slower-than-expected ramp-up in sequencing by our small- to mid-sized customers, many of whom are new to PacBio. The time for new Revio customers and new projects to reach full capacity has been slower than previously anticipated;

·Sample delays impacting sequencing volume in the quarter at certain large customers; and,

·Some service providers in China operating at lower utilization as a result of the difficult funding environment.

 

Commentary by Christian Henry, President and CEO of PacBio:

 

"Following the successful launch of the Revio system and a record 2023, we entered the year with optimism regarding our growth prospects. As we reached the last couple of weeks of the first quarter, however, we saw an increasing number of customers delay instrument purchases and we experienced some unexpected softness in consumable shipments. As a result, the first quarter came in below our original expectations. We expect these factors to have an impact on our 2024 performance, and we expect to provide further details on our full year outlook on our earnings call scheduled for May 9, 2024.”

 

 

 

 

“Looking ahead, we are focused on four strategic priorities. First, improving commercial execution to drive adoption of both the Revio and Onso platforms; second, continuing the development of our benchtop long read and high throughput short-read platforms; third, implementing projects to improve our gross margin and drive manufacturing efficiencies; and finally, reducing annualized run-rate operating expenses on a non-GAAP basis by $50 million to $75 million by the end of 2024 in relation to our prior guidance of 5% operating expense growth. ”

 

“Despite these near-term headwinds, we remain highly encouraged by PacBio’s long-term growth potential. We are continuing to see new customers adopt Revio as evidenced by the fact that nearly 60% of our Revio placements in the quarter were to new customers. We are also starting to see significant traction with large-scale projects, such as the Estonia National Biobank project announced last month, the first Revio in Latin America to be used for a 1,000-sample whole genome project, and pediatric genome initiatives at hospitals in Canada and Korea. Additionally, we expect consumables to return to sequential growth going forward this year as we continue to grow the Revio installed base and see encouraging trends that point toward increased sequencing on the Revio system. It should be noted that March Revio utilization was at an all-time high – including some of our top customers exceeding our expectations. We have expanded the capabilities of the Revio platform through the roll-out of v13 software upgrade which has enabled our customers with more functionality and better performance. We’ve also recently launched new reagent kits that improve our customer workflows and launched our new Kinnex kits to continue to drive new customer adoption.”

 

“I am confident in our ability to create value for all our stockholders and stakeholders. PacBio has some of the world’s most advanced sequencing technology and our customers continue to uncover insights into the genome unimaginable with other technologies.”

 

Updated Guidance and Financial Outlook

 

Revenue in the first quarter was significantly lower than expected, and as a result, PacBio now expects 2024 revenue to be in the range of $170 million to $200 million. The company believes that second quarter revenue will improve over the first quarter and that the second half of the year will improve sequentially as consumables return to sequential growth and the company closes some of the deals that were delayed in the first quarter. At the midpoint of $185 million, the company believes that total Revio shipments for 2024 will be around 120 systems. At the midpoint of the revised guidance, the company expects that consumable revenue will be around $80 million and consumable pull-through on the Revio system will be around $290,000 per system.

 

Given the company’s lowered outlook for 2024, PacBio believes it is unlikely to achieve its long-term revenue guidance of at least $500 million in 2026 and is reevaluating the timing of achieving it. The company expects to provide more details on its financial performance and outlook on its earnings call scheduled on May 9, 2024.

 

With the reduced revenue forecast and the planned cost reduction initiatives, PacBio currently expects to end 2024 with cash, cash equivalents, and investments balance in the range of $435 million to $450 million

 

The preliminary unaudited financial information set forth above is subject to revision and is anticipated to be finalized in May 2024. PacBio's financial results could differ materially from the preliminary estimates above, which are not a comprehensive statement of PacBio's financial results and are not necessarily indicative of the results to be expected as of or for the fiscal period ended March 31, 2024, or any future period. Accordingly, you should not place undue reliance on these preliminary estimates. 

 

Quarterly Conference Call Information

 

PacBio will hold its quarterly conference call on Thursday, May 9, 2024, at 5:00 p.m. Eastern Time to discuss its first quarter 2024 financial results. The call will be webcast and may be accessed at PacBio’s website at https://investor.pacificbiosciences.com/.

 

Date: Thursday, May 9, 2024, at 5:00 pm ET (2:00 pm PT)

 

Listen live via internet or replay: https://investor.pacificbiosciences.com/

 

Toll-free: 1-888-349-0136

 

International: 1-412-317-0459

 

If using the dial-in option, please dial into the call ten minutes prior to start time using the appropriate number above and ask to join the “PacBio Q1 Earnings Call.”

 

 

 

 

About PacBio

 

PacBio (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.

 

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

 

Statement regarding use of non-GAAP financial measures

 

This press release refers to non-GAAP operating expenses, which PacBio reports in addition to, and not as a substitute for, financial measures calculated in accordance with GAAP. For more information on how PacBio defines non-GAAP operating expenses, see the tables included with our fourth quarter 2023 earnings press release dated February 15, 2024. PacBio is unable to reconcile the non-GAAP operating expense numbers included in this press release because certain items that impact this measure are out of PacBio's control and/or cannot be reasonably predicted at this time.

 

PacBio believes that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP information is not superior to financial measures calculated in accordance with GAAP, is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of PacBio’s non-GAAP financial measures as tools for comparison. 

 

Forward-Looking Statements

 

This press release contains “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including statements relating to PacBio’s preliminary unaudited financial information as of and for the periods ended March 31, 2024; the availability or timing of PacBio’s final financial results as of and for the periods ended March 31, 2024; PacBio’s expectations for future operating results, revenue and guidance; PacBio’s cost-saving plans and initiatives as well as the expected financial impact and timing of these plans and initiatives; risks that the operating expense reductions may have an adverse impact on PacBio’s business and results of operations; risks that charges associated with the Company’s operating expense reductions may be greater than anticipated; the availability, uses, accuracy, coverage, advantages, quality or performance of, or benefits or expected benefits of using, PacBio products or technologies; anticipated demand for PacBio’s products and technologies in future periods. Reported results and orders for any instrument system should not be considered an indication of future performance. You should not place undue reliance on forward-looking statements because they are subject to assumptions, risks, and uncertainties that could cause actual outcomes and results to differ materially from currently anticipated results. These risks include, but are not limited to, challenges inherent in developing, manufacturing, launching, marketing and selling new products, and achieving anticipated new sales; potential cancellation of existing instrument orders; assumptions, risks and uncertainties related to the ability to attract new customers and retain and grow sales from existing customers; risks related to lengthening sales cycles; risks related to PacBio's ability to successfully execute and realize the benefits of acquisitions; the estimated size and estimated growth for the markets for PacBio’s products may be smaller than expected; the impact of U.S. export restrictions on the shipment of PacBio products to certain countries; rapidly changing technologies and extensive competition in genomic sequencing; unanticipated increases in costs or expenses; interruptions or delays in the supply of components or materials for, or manufacturing of, PacBio products and products under development; potential product performance and quality issues and potential delays in development and commercialization timelines; the possible loss of key employees, customers, or suppliers; customers and prospective customers curtailing or suspending activities using PacBio's products; third-party claims alleging infringement of patents and proprietary rights or seeking to invalidate PacBio's patents or proprietary rights; risks associated with international operations; and other risks associated with general macroeconomic conditions and geopolitical instability. Additional factors that could materially affect actual results can be found in PacBio's most recent filings with the Securities and Exchange Commission, including PacBio's most recent reports on Forms 8-K, 10-K, and 10-Q, and include those listed under the caption “Risk Factors.” These forward-looking statements, including PacBio’s preliminary unaudited financial information and PacBio’s financial guidance, are based on current expectations and speak only as of the date hereof; except as required by law, PacBio disclaims any obligation to revise or update these forward-looking statements to reflect events or circumstances in the future, even if new information becomes available.

 

Contacts

 

Investors:

Todd Friedman

650.521.8450

ir@pacb.com

 

Media:

Lizelda Lopez

pr@pacb.com

 

 

 

 

EX-101.SCH 3 pacb-20240416.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 pacb-20240416_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 pacb-20240416_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Cover
Apr. 16, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Apr. 16, 2024
Entity File Number 001-34899
Entity Registrant Name Pacific Biosciences of California, Inc.
Entity Central Index Key 0001299130
Entity Tax Identification Number 16-1590339
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 1305 O’Brien Drive
Entity Address, City or Town Menlo Park
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94025
City Area Code 650
Local Phone Number 521-8000
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per share
Trading Symbol PACB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://pacb.com/role/Cover Cover Cover 1 false false All Reports Book All Reports pacb-20240416.xsd pacb-20240416_lab.xml pacb-20240416_pre.xml tm2411926d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2411926d1_8k.htm": { "nsprefix": "PACB", "nsuri": "http://pacb.com/20240416", "dts": { "schema": { "local": [ "pacb-20240416.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "pacb-20240416_lab.xml" ] }, "presentationLink": { "local": [ "pacb-20240416_pre.xml" ] }, "inline": { "local": [ "tm2411926d1_8k.htm" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 22 }, "report": { "R1": { "role": "http://pacb.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-04-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2411926d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-04-16", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2411926d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://pacb.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-24-047511-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-047511-xbrl.zip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end XML 17 tm2411926d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001299130 2024-04-16 2024-04-16 iso4217:USD shares iso4217:USD shares false 0001299130 8-K 2024-04-16 Pacific Biosciences of California, Inc. DE 001-34899 16-1590339 1305 O’Brien Drive Menlo Park CA 94025 650 521-8000 false false false false Common Stock, par value $0.001 per share PACB NASDAQ false